GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alivus Life Sciences Ltd (NSE:ALIVUS) » Definitions » Net Income

Alivus Life Sciences (NSE:ALIVUS) Net Income : ₹4,417 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alivus Life Sciences Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Alivus Life Sciences's Net Income for the three months ended in Dec. 2024 was ₹1,370 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was ₹4,417 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Alivus Life Sciences's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was ₹11.14.


Alivus Life Sciences Net Income Historical Data

The historical data trend for Alivus Life Sciences's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alivus Life Sciences Net Income Chart

Alivus Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Income
Get a 7-Day Free Trial 3,130.98 3,515.81 4,187.24 4,669.61 4,708.88

Alivus Life Sciences Quarterly Data
Mar19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,187.65 979.36 1,114.83 953.16 1,369.60

Alivus Life Sciences Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Alivus Life Sciences's Net Income for the fiscal year that ended in Mar. 2024 is calculated as

Net Income(A: Mar. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=6312.9+-1604.02+0+9.0949470177293E-13
=4,709

Alivus Life Sciences's Net Income for the quarter that ended in Dec. 2024 is calculated as

Net Income(Q: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=1851.47+-481.87+0+0
=1,370

Net Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4,417 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alivus Life Sciences  (NSE:ALIVUS) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Alivus Life Sciences's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Alivus Life Sciences Net Income Related Terms

Thank you for viewing the detailed overview of Alivus Life Sciences's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Alivus Life Sciences Business Description

Traded in Other Exchanges
Address
470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd, formerly Glenmark Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Alivus Life Sciences Headlines

No Headlines